Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection.

Heuft MM, Houba SM, van den Berk GE, Smissaert van de Haere T, van Dam AP, Dijksman LM, Regez RM, Brinkman K.

AIDS. 2014 Apr 24;28(7):999-1005. doi: 10.1097/QAD.0000000000000180.

PMID:
24685742
2.

Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.

Gatanaga H, Hayashida T, Tanuma J, Oka S.

Clin Infect Dis. 2013 Jun;56(12):1812-9. doi: 10.1093/cid/cit145. Epub 2013 Mar 13.

PMID:
23487374
3.

Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.

Mutwa PR, Boer KR, Rusine JB, Muganga N, Tuyishimire D, Reiss P, Lange JM, Geelen SP.

Pediatr Infect Dis J. 2013 Mar;32(3):246-51. doi: 10.1097/INF.0b013e318271b93d.

PMID:
22976050
4.

Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.

Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM.

J Med Virol. 2007 Oct;79(10):1464-71.

PMID:
17705185
5.

High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.

Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH.

J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):203-8. doi: 10.1097/MPG.0b013e3181819ad4.

PMID:
19179883
6.

Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan.

Sun HY, Cheng CY, Lee NY, Yang CJ, Liang SH, Tsai MS, Ko WC, Liu WC, Wu PY, Wu CH, Lin HH, Hung CC.

PLoS One. 2014 Feb 26;9(2):e90194. doi: 10.1371/journal.pone.0090194. eCollection 2014.

7.

Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.

Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC.

Clin Infect Dis. 2007 Nov 1;45(9):1221-9. Epub 2007 Sep 21.

PMID:
17918088
8.

[Investigation of occult hepatitis B in HIV infected patients].

Altınbaş A, Ergünay K, Calık Başaran N, Alp A, Turgut D, Hasçelik G, Uzun Ö, Unal S.

Mikrobiyol Bul. 2011 Apr;45(2):353-8. Turkish.

PMID:
21644079
9.

HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.

Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.

PMID:
23892239
10.

Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.

Shilaih M, Marzel A, Scherrer AU, Braun DL, Kovari H, Rougemont M, Darling K, Battegay M, Hoffmann M, Bernasconi E, Hirzel C, Günthard HF, Kouyos RD; Swiss HIV Cohort Study a; Swiss HIV Cohort Study.

J Infect Dis. 2016 Aug 15;214(4):599-606. doi: 10.1093/infdis/jiw195. Epub 2016 May 18.

PMID:
27190182
11.

[Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].

Zhang RF, Liu L, Zheng YF, Shen YZ, Chen J, Gu SM, Wang JR, Lu HZ.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):189-91. Chinese.

PMID:
23967739
12.

High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.

Laurent C, Bourgeois A, Mpoudi-Ngolé E, Kouanfack C, Ciaffi L, Nkoué N, Mougnutou R, Calmy A, Koulla-Shiro S, Ducos J, Delaporte E.

HIV Med. 2010 Jan;11(1):85-9. doi: 10.1111/j.1468-1293.2009.00742.x. Epub 2009 Jul 29.

13.

Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.

Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI.

J Med Virol. 2009 Mar;81(3):441-5. doi: 10.1002/jmv.21422.

PMID:
19152397
14.
15.

Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.

French AL, Lin MY, Evans CT, Benning L, Glesby MJ, Young MA, Operskalski EA, Augenbraun M, Peters M.

Clin Infect Dis. 2009 Jul 1;49(1):148-54. doi: 10.1086/599610.

16.

Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort Study.

Falade-Nwulia O, Seaberg EC, Snider AE, Rinaldo CR, Phair J, Witt MD, Thio CL.

Ann Intern Med. 2015 Nov 3;163(9):673-80. doi: 10.7326/M15-0547. Epub 2015 Oct 13.

17.

Development of chronic hepatitis B virus infection in hepatitis B surface antigen negative HIV/HBV co-infected adults: a rare opportunistic illness.

Landrum ML, Roediger MP, Fieberg AM, Weintrob AC, Okulicz JF, Crum-Cianflone NF, Ganesan A, Lalani T, Macalino GE, Chun HM.

J Med Virol. 2011 Sep;83(9):1537-43. doi: 10.1002/jmv.22155.

PMID:
21739443
18.

High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda.

Rusine J, Ondoa P, Asiimwe-Kateera B, Boer KR, Uwimana JM, Mukabayire O, Zaaijer H, Mugabekazi J, Reiss P, van de Wijgert JH.

PLoS One. 2013 May 22;8(5):e63303. doi: 10.1371/journal.pone.0063303. Print 2013.

19.

Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.

Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, van Marle G, Gill MJ.

J Clin Virol. 2014 Aug;60(4):347-53. doi: 10.1016/j.jcv.2014.04.021. Epub 2014 May 4.

PMID:
24881491
20.

Ten-year follow-up study of hepatitis B virus infection and vaccination status in hospital employees.

Rosen E, Rudensky B, Paz E, Isacsohn M, Jerassi Z, Gottehrer NP, Yinnon AM.

J Hosp Infect. 1999 Mar;41(3):245-50.

PMID:
10204128

Supplemental Content

Support Center